Lantheus (NASDAQ:LNTH) Updates FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2024 earnings guidance on Wednesday. The company provided EPS guidance of 6.650-6.700 for the period, compared to the consensus EPS estimate of 6.660. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion. Lantheus also updated its FY24 guidance to $6.65-6.70 EPS.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. B. Riley upped their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Leerink Partners upped their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday. Finally, JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Stock Performance

LNTH stock traded down $1.93 during midday trading on Friday, hitting $86.39. The company’s stock had a trading volume of 931,908 shares, compared to its average volume of 990,024. The stock’s 50-day moving average price is $107.71 and its 200 day moving average price is $95.52. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a market cap of $6.00 billion, a price-to-earnings ratio of 14.66 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $378.73 million for the quarter, compared to analysts’ expectations of $373.58 million. On average, equities analysts forecast that Lantheus will post 5.99 EPS for the current year.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 2.10% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.